Annual Revenue Comparison: Bio-Techne Corporation vs Travere Therapeutics, Inc.

Bio-Techne vs. Travere: A Decade of Revenue Growth

__timestampBio-Techne CorporationTravere Therapeutics, Inc.
Wednesday, January 1, 201435776300028203205
Thursday, January 1, 201545224600099892000
Friday, January 1, 2016499023000133591000
Sunday, January 1, 2017563003000154937000
Monday, January 1, 2018642993000164246000
Tuesday, January 1, 2019714006000175338000
Wednesday, January 1, 2020738691000198321000
Friday, January 1, 2021931032000227490000
Saturday, January 1, 20221105599000212018000
Sunday, January 1, 20231136702000145238000
Monday, January 1, 20241159060000
Loading chart...

Unveiling the hidden dimensions of data

A Decade of Revenue Growth: Bio-Techne vs. Travere Therapeutics

In the ever-evolving biotech industry, revenue growth is a key indicator of a company's success and market position. Over the past decade, Bio-Techne Corporation has demonstrated a remarkable upward trajectory in its annual revenue, growing by over 220% from 2014 to 2023. This growth reflects Bio-Techne's strategic innovations and market expansions.

In contrast, Travere Therapeutics, Inc. has experienced a more modest revenue increase of approximately 415% over the same period, peaking in 2021. However, the data for 2024 is missing, which could indicate a potential shift or anomaly in their financial reporting.

This comparison highlights the dynamic nature of the biotech sector, where companies must continuously adapt to maintain their competitive edge. Investors and industry analysts will find these insights crucial for understanding market trends and making informed decisions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025